Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

C

Cytos Biotechnology

Status and phase

Completed
Phase 2

Conditions

Perennial Allergy to House Dust Mite and/or Cat

Treatments

Drug: CYT003-QbG10

Study type

Interventional

Funder types

Industry

Identifiers

NCT00575003
CYT003-QbG10 08

Details and patient eligibility

About

The purpose of the study is to test the efficacy of a vaccine against house dust mite and/or cat allergy compared to placebo in adult patients.

Enrollment

64 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Mild to moderate perennial allergic rhinoconjunctivitis due to hypersensitization towards house dust mite and/or cat allergens

Exclusion criteria

  • Clinical relevant other allergies (perennial or seasonal) that could potentially interfere with the patient's study treatment schedule or assessments.
  • Use of any concomitant medication that could affect the patient's study treatment response or assessment results.
  • Any clinically relevant concomitant disease as judged by the investigator.
  • Pregnancy or female planning to become pregnant during the study.

Trial design

64 participants in 2 patient groups, including a placebo group

1
Experimental group
Treatment:
Drug: CYT003-QbG10
2
Placebo Comparator group
Treatment:
Drug: CYT003-QbG10

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems